Your email has been successfully added to our mailing list.

×
-0.00357142857142863 -0.0102040816326531 0.0408163265306122 0.010204081632653 0.020408163265306 0.0383673469387755 0.193877551020408 0.153061224489796
Stock impact report

Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance

RITTER PHARMACEUTICALS (RTTR) 
Last ritter pharmaceuticals earnings: 8/14 05:11 pm Check Earnings Report
US:NASDAQ Investor Relations: ritterpharmaceuticals.com/investors
Company Research Source: GlobeNewswire
Top-line Data Readout on Target for early Q4 2019 LOS ANGELES, May 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today announced that the final patient in its first pivotal Phase 3 clinical trial of RP-G28 for the potential treatment of Lactose intolerance (LI), a study known as the “Liberatus” study (NCT03597516), has completed the 30-day treatment dosing period. “We are excited to announce that the last of the 557 enrolled patients in our Liberatus trial has completed dosing and we remain on track for data readout in early Q4 2019,” said Andrew J. Ritter, CEO of Ritter Pharmaceuticals. “With patient completion of the 30-day treatment period, approximately 43%, or 240 patients are continuing at various points through the 90-day “real-world” observational portion of the trial, while approxima Show less Read more
Impact Snapshot
Event Time:
RTTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for RTTR alerts
Opt-in for
RTTR alerts

from News Quantified
Opt-in for
RTTR alerts

from News Quantified